Browsing Tag
Orphan Drug Designation
14 posts
Phanes Therapeutics’ PT217 receives FDA orphan drug designation for neuroendocrine carcinoma
Phanes Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing oncology treatments, has achieved a significant milestone with…
August 18, 2024
Alexion Pharmaceuticals secures FDA priority review for SOLIRIS in neuromyelitis optica spectrum disorder
Alexion Pharmaceuticals has secured a significant milestone with the FDA granting priority review for its C5 complement inhibitor,…
February 23, 2019
Biohaven secures orphan drug status for verdiperstat in MSA treatment
Connecticut-based Biohaven Pharmaceutical has received a significant regulatory boost, with the US FDA granting orphan drug designation for…
February 20, 2019
Mereo BioPharma completes patient enrollment for BPS-804 Phase 2b trial in osteogenesis imperfecta
British specialty biopharma company Mereo BioPharma Group has completed patient enrollment for a Phase 2b clinical trial of…
October 30, 2018